Biotech Innovator Equillium Announces Expansion of Cryptocurrency Reserve Strategy
Biotechnology innovator Equillium has announced a strategic expansion, integrating a cryptocurrency reserve strategy as part of its broader financial and growth objectives. Equillium CEO Bruce Steel stated, “We are actively evaluating the company’s strategic options, and I am pleased to announce that we have incorporated digital currencies into our financial strategy to fully leverage their diversification, liquidity, and long-term capital appreciation potential.” “Following a comprehensive review of the industry, the board and I unanimously believe that adding this strategy is in the best interests of our shareholders, and we have accordingly updated our financial investment policy. We look forward to providing further updates on this strategy in the third quarter of 2025.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
